Loading...

Codexis, Inc.

0I0X.LLSE
Healthcare
Biotechnology
£2.70
£0.05(1.89%)

Codexis, Inc. (0I0X.L) Company Profile & Overview

Explore Codexis, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Codexis, Inc. (0I0X.L) Company Profile & Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

SectorHealthcare
IndustryBiotechnology
CEOStephen George Dilly MBBS,

Contact Information

650 421 8100
200 Penobscot Drive, Redwood City, CA, 94063

Company Facts

188 Employees
IPO DateJan 29, 2018
CountryUS
Actively Trading

Frequently Asked Questions

;